Calpain inhibition by calpeptin does not prevent APLT activity reduction in PS-exposing platelets, but calpeptin has independent pro-apoptotic effects

Summary

Exposure of procoagulant phosphatidylserine (PS) on the surface of activated platelets is not readily reversible and this may propagate thrombosis. Persistence of PS exposure may be attributed, at least in part, to a continued reduction of the activity of aminophospholipid translocase (APLT), that transports PS from the outer to the inner membrane leaflet. We investigated whether calpain is involved in the inhibition of APLT activity. In flow cytometric investigations, using the inhibitors calpeptin or E64d at a concentration that blocks calpain activation, we found that calpain is not responsible for the reduction in APLT activity that results in persistence of PS exposure. Unexpectedly, we found that the inhibitors had additional effects independent of blocking calpain. Incubation of resting platelets with calpeptin resulted in a subpopulation of platelets with increased intracellular Ca²⁺ and persistent PS exposure. The inhibitors also increased the proportion of platelets with persistent PS exposure in suspensions stimulated with thrombin and/or collagen or the Ca²⁺-ionophore A23187 under conditions in which calpain was not activated or in which its activation was completely blocked; P-selectin expression on thrombin and/ or collagen-stimulated platelets was inhibited. Furthermore, in stimulated platelets, calpeptin increased the proportion of the PS-exposing platelets expressing a second apoptotic hallmark, collapsed mitochondrial inner membrane potential (ΔΨ_m). These additional effects of calpeptin on platelet regulation of intracellular Ca²⁺ levels and apoptotic-like events should be taken into account when it is used as an inhibitor of calpain.

Keywords

Calpain - calpeptin - PS expression - apoptosis - aminophospholipid translocase

• References

• 1 Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132.
• 2 Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004; 1636: 119-128.
• 3 Wolfs JL, Comfurius P, Rasmussen JT. et al. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 2005; 62: 1514-1525.
• 4 Sune A, Bette-Bobillo P, Bienvenue A. et al. Selective outside-inside translocation of aminophospholipids in human platelets. Biochemistry 1987; 26: 2972-2978.
• 5 Daleke DL, Lyles JV. Identification and purification of aminophospholipid flip-pases. Biochim Biophys Acta 2000; 1486: 108-127.
• 6 Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193.
• 7 Kenis H, Hofstra L, Reutelingsperger CP. Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell Mol Life Sci 2007; 64: 2859-2862.
• 8 Hammill AK, Uhr JW, Scheuermann RH. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res 1999; 251: 16-21.
• 9 Leung R, Gwozdz AM, Wang H. et al. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and amino -phospholipid translocase activity. J Thromb Haemost 2007; 05: 560-570.
• 10 Rand ML, Wang H, Bang KW. et al. Persistence of phosphatidylserine exposure on activated platelets in vivo in rabbits. Thromb Haemost 2007; 98: 477-478.
• 11 Comfurius P, Bevers EM, Zwaal RF. Interaction between phosphatidylserine and the isolated cytoskeleton of human blood platelets. Biochim Biophys Acta 1989; 983: 212-216.
• 12 Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62: 971-988.
• 13 Pasquet JM, Dachary-Prigent J, Nurden AT. Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. Eur J Biochem 1996; 239: 647-654.
• 14 Schoenwaelder SM, Kulkarni S, Salem HH. et al. Distinct substrate specificities and functional roles for the 78– and 76-kDa forms of mu-calpain in human platelets. J Biol Chem 1997; 272: 24876-24884.
• 15 Schoenwaelder SM, Yuan Y, Jackson SP. Calpain regulation of integrin alpha IIb beta 3 signaling in human platelets. Platelets 2000; 11: 189-198.
• 16 Fox JE. On the role of calpain and Rho proteins in regulating integrin-induced signaling. Thromb Haemost 1999; 82: 385-391.
• 17 Fox JE. Cytoskeletal proteins and platelet signaling. Thromb Haemost 2001; 86: 198-213.
• 18 Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem 2004; 279: 30697-30706.
• 19 Croce K, Flaumenhaft R, Rivers M. et al. Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J Biol Chem 1999; 274: 36321-36327.
• 20 Wolf BB, Goldstein JC, Stennicke HR. et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 1999; 94: 1683-1692.
• 21 Augereau O, Rossignol R, DeGiorgi F. et al. Apoptotic-like mitochondrial events associated to phosphatidylserine exposure in blood platelets induced by local an-aesthetics. Thromb Haemost 2004; 92: 104-113.
• 22 Shcherbina A, Remold-O’Donnell E. Role of caspase in a subset of human platelet activation responses. Blood 1999; 93: 4222-4231.
• 23 Dachary-Prigent J, Freyssinet JM, Pasquet JM. et al. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993; 81: 2554-2565.
• 24 Bachelot-Loza C, Badol P, Brohard-Bohn B. et al. Differential regulation of platelet aggregation and aminophospholipid exposure by calpain. Br J Haematol 2006; 133: 419-426.
• 25 Rukoyatkina N, Begonja AJ, Geiger J. et al. Phosphatidylserine surface expression and integrin alpha IIb beta 3 activity on thrombin/convulxin stimulated platelets/ particles of different sizes. Br J Haematol 2009; 144: 591-602.
• 26 Siljander P, Farndale RW, Feijge MA. et al. Platelet adhesion enhances the glyco-protein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol 2001; 21: 618-627.
• 27 Briede JJ, Heemskerk JW, Hemker HC. et al. Heterogeneity in microparticle formation and exposure of anionic phospholipids at the plasma membrane of single adherent platelets. Biochim Biophys Acta 1999; 1451: 163-172.
• 28 Leytin V, Allen DJ, Mutlu A. et al. Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest 2009; 89: 374-384.
• 29 Munnix IC, Cosemans JM, Auger JM. et al. Platelet response heterogeneity in thrombus formation. Thromb Haemost 2009; 102: 1149-1156.
• 30 Tsujinaka T, Kajiwara Y, Kambayashi J. et al. Synthesis of a new cell penetrating cal-pain inhibitor (calpeptin). Biochem Biophys Res Commun 1988; 153: 1201-1208.
• 31 McGowan EB, Becker E, Detwiler TC. Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d. Biochem Biophys Res Commun 1989; 158: 432-435.
• 32 Remenyi G, Szasz R, Friese P. et al. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005; 25: 467-471.
• 33 Molnar J, Lorand L. Studies on apyrases. Arch Biochem Biophys 1961; 93: 353-363.
• 34 Mustard JF, Kinlough-Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol 1989; 169: 3-11.
• 35 Kinlough-Rathbone RL, Perry DW, Rand ML. et al. Most apyrase preparations are impure and contain inhibitors of cathepsin G: suggestions for use of apyrase in preparation and stabilization of platelet suspensions. Thromb Haemost 1999; 81: 849-850.
• 36 Rand ML, Wang H, Bang KW. et al. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J Thromb Haemost 2004; 02: 651-659.
• 37 Poot M, Gibson LL, Singer VL. Detection of apoptosis in live cells by MitoTracker red CMXRos and SYTO dye flow cytometry. Cytometry 1997; 27: 358-364.
• 38 Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest 1964; 43: 843-855.
• 39 Chang CP, Zhao J, Wiedmer T. et al. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 1993; 268: 7171-7178.
• 40 Keuren JF, Wielders SJ, Ulrichts H. et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005; 25: 1499-1505.
• 41 Rand ML, Wang H, Bang KW. et al. Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. J Thromb Haemost 2006; 04: 1621-1623.
• 42 Fox JE, Reynolds CC, Austin CD. The role of calpain in stimulus-response coupling: evidence that calpain mediates agonist-induced expression of procoagulant activity in platelets. Blood 1990; 76: 2510-2519.
• 43 Fox JE, Taylor RG, Taffarel M. et al. Evidence that activation of platelet calpain is induced as a consequence of binding of adhesive ligand to the integrin, glycoprotein IIb-IIIa. J Cell Biol 1993; 120: 1501-1507.
• 44 Kinlough-Rathbone RL, Perry DW. Prolonged expression of procoagulant activity of human platelets degranulated by thrombin. Thromb Haemost 1995; 74: 958-961.
• 45 Schoenwaelder SM, Burridge K. Evidence for a calpeptin-sensitive protein-tyro-sine phosphatase upstream of the small GTPase Rho. A novel role for the calpain inhibitor calpeptin in the inhibition of protein-tyrosine phosphatases. J Biol Chem 1999; 274: 14359-14367.
• 46 Carafoli E, Molinari M. Calpain: a protease in search of a function?. Biochem Biophys Res Commun 1998; 247: 193-203.
• 47 Kuchay SM, Chishti AH. Calpain-mediated regulation of platelet signaling pathways. Curr Opin Hematol 2007; 14: 249-254.
• 48 Azam M, Andrabi SS, Sahr KE. et al. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol 2001; 21: 2213-2220.
• 49 Dachary-Prigent J, Pasquet JM, Nurden AT. Simultaneous detection of changes in cytoplasmic Ca(2+), aminophospholipid exposure and micro-vesiculation in activated platelets. Platelets 1997; 08: 405-412.
• 50 London FS, Marcinkiewicz M, Walsh PN. PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium. Biochemistry 2006; 45: 7289-7298.
• 51 Sims PJ, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb Haemost 2001; 86: 266-275.
• 52 Leytin V, Allen DJ, Mykhaylov S. et al. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006; 04: 2656-2663.
• 53 Jobe SM, Wilson KM, Leo L. et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood 2008; 111: 1257-1265.
• 54 Schoenwaelder SM, Yuan Y, Josefsson EC. et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-666.